The beginning of 2026 brought one of the biggest changes to the GLP-1 medication landscape as a new medication for weight loss was approved, called orforglipron
Activation of this pathway, initiated by the downstream adaptor protein MyD88, results in nuclear factor-B (NF-B) activation and nuclear translocation (61, 63)
These SCFAs can interact with L-cells in the intestinal lining and may influence GLP-1 secretion
Post incubation, the liberated IGF-1 was co-immunoaffinity extracted with the internal reference, using protein A/G MSIA pipette tips (from Thermo Fisher Scientific) loaded with antihuman IGF-1 antibody
Will melatonin help with pregnancy insomnia
Be patient with dose escalation The system is designed for weeks, not days of adjustment